SoftOx Solutions AS (“SoftOx” or “the Company”) addresses a limitation that antibiotics have not overcome: bacteria embedded in biofilm within the airways of patients with cystic fibrosis (“CF”) and non-CF bronchiectasis (“NCFB”), where treatment suppresses the infection without eradicating it. SoftOx Inhalation Solution (“SIS”) stabilizes hypochlorous acid, an endogenous antimicrobial produced by the body’s neutrophils, and delivers it by nebulization into the airway together with an organic acid. With a pan-antimicrobial mechanism, safety established in two clinical studies and proof of concept expected during H1-27, Analyst Group considers SoftOx well positioned ahead of its key value inflection. Based on an rNPV model, we derive a present value of NOK 0.20 per share in a Base scenario, rising to approx. NOK 0.30 following a positive readout, with or without a subsequent licensing agreement.

SoftOx Solutions AS (“SoftOx” or “the Company”) addresses a limitation that antibiotics have not overcome: bacteria embedded in biofilm within the airways of patients with cystic fibrosis (“CF”) and non-CF bronchiectasis (“NCFB”), where treatment suppresses the infection without eradicating it. SoftOx Inhalation Solution (“SIS”) stabilizes hypochlorous acid, an endogenous antimicrobial produced by the body’s neutrophils, and delivers it by nebulization into the airway together with an organic acid. With a pan-antimicrobial mechanism, safety established in two clinical studies and proof of concept expected during H1-27, Analyst Group considers SoftOx well positioned ahead of its key value inflection. Based on an rNPV model, we derive a present value of NOK 0.20 per share in a Base scenario, rising to approx. NOK 0.30 following a positive readout, with or without a subsequent licensing agreement.

Read the equity research report here

About Analyst Group: One of the Nordics’ leading equity research boutiques with focus on small and medium-sized listed companies.Read more about Analyst Group This is a press release from Analyst Group regarding the publication of a comment on SoftOx Solutions. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.